E. Fegelman et al., SQUAMOUS-CELL CARCINOMA OF THE ESOPHAGUS WITH MUCIN-SECRETING COMPONENT - MUCOEPIDERMOID CARCINOMA, Journal of thoracic and cardiovascular surgery, 107(1), 1994, pp. 62-67
Among 1058 patients with cancer of the esophagus, 20 patients with muc
oepidermoid or adenosquamous cell carcinoma of the esophagus and cardi
a, together defined as squamous cell carcinoma with a mucin-secreting
component, were seen over a 10-year period. Their records were reviewe
d and appropriate comparisons were also made with the more common squa
mous cell carcinomas and adenocarcinomas. Squamous cell carcinoma with
mucin-secreting component comprised 1.9 % of all tumors encountered.
Clinical features including age, male predominance, symptoms at presen
tation, length of tumor, and appearance of tumor did not differ from t
hose of squamous cell and adenocarcinoma, The location of these tumors
, however, followed that of squamous cell carcinomas, with 55 % in the
middle third and 25 % in the lower third. Adenocarcinomas were found
predominantly at the cardia (83 %). Operability and resectability rate
s were higher than those of squamous cell and adenocarcinomas. Primary
treatment consisted of resection in 19 of the 20 patients (95 %); 18
of them had a one-stage resection and 1 patient had a two-stage resect
ion. Postresection staging showed that 5 % had stage I disease, 16 % h
ad stage II, and 79 % had stage m disease. None of the patients who un
derwent resection died within 30 days of the operation, The mortality
after 30 days was 10.5 %. The 1 patient in whom intubation was the pri
mary treatment had distant metastases at the time of presentation (sta
ge IV). The overall median survival was 9.2 months. The median surviva
l for patients who had their tumors resected was 9.5 months. The survi
val improved to 33 months for curative resection but was only 8.7 mont
hs for palliative resection. The 1-, 2-, and 5-year survivals were 46
%, 39 %, and 0 %, respectively. This prognosis was not significantly d
ifferent from that of patients with squamous cell carcinoma or adenoca
rcinoma.